Cancer biomarker profiling in patients with chronic hepatitis C virus, liver cirrhosis and hepatocellular carcinoma

Costantini,Susan; Capone,Francesca; Maio,Patrizia; Guerriero,Eliana; Colonna,Giovanni; Izzo,Francesco; Castello,Giuseppe

doi:10.3892/or.2013.2378

Cancer biomarker profiling in patients with chronic hepatitis C virus, liver cirrhosis and hepatocellular carcinoma

Authors:
- Susan Costantini
- Francesca Capone
- Patrizia Maio
- Eliana Guerriero
- Giovanni Colonna
- Francesco Izzo
- Giuseppe Castello
View Affiliations

Affiliations: National Cancer Institute ‘G. Pascale Foundation’ - Oncology Research Center of Mercogliano (CROM), Mercogliano, Italy, Department of Infectious Diseases, ‘San Giuseppe Moscati’ Hospital, Avellino, Italy, Department of Biochemistry and Biophysics, Second University of Naples, Naples, Italy, National Cancer Institute of Naples, ‘G. Pascale Foundation’, Naples, Italy
Published online on: April 3, 2013 https://doi.org/10.3892/or.2013.2378
Pages: 2163-2168

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The detection and diagnosis of hepatocellular carcinoma (HCC) at an early stage may significantly affect the prognosis of HCC patients. Thus, it is necessary to always identify novel putative markers for improving diagnosis. Hepatocarcinogenesis correlates with pathological hepatic angiogenesis. However, each tumor-induced angiogenetic process is influenced by the microenvironment through several pro- and anti-angiogenic factors released from tumor cells, tumor-associated inflammatory cells and/or from the extracellular matrix, and modulated by various signal pathways. In this study, we evaluated the profiling of angiogenic factors using Bio-Plex Pro™ Human Cancer Biomarker Panel 1, a 16-plex magnetic bead-based assay, in sera of patients with chronic hepatitis C (CHC) virus, liver cirrhosis (LC) and HCC. Our results demonstrated: i) high levels of hepatocyte growth factor (HGF) and prolactin only in LC and HCC patients, ii) high levels of soluble human epidermal growth factor receptor‑2 (sHER-2/neu; ErbB-2), sIL-6Ra, leptin (LEP) and platelet endothelial cell adhesion molecule‑1 (PECAM-1) in CHC, LC and HCC patients and iii) that sIL-6R correlated with the fibrosis stage in CHC patients, with Child‑Pugh score in those patients with LC and with tumor size in those patients with HCC, confirming that this protein may be used as a predictor of liver damage and of inflammatory process leading to fibrosis, cirrhosis, and subsequently to cancer. Moreover, an interactomic study conducted using the Ingenuity Pathway Analysis (IPA) software proved the existence of a correlation between 5 significant proteins [ErbB-2, sIL-6Ra, prolactin (PRL), HGF and LEP] which are involved in the same metabolic pathways.

View Figures

View References

1	Fusco M, Girardi E, Piselli P, Palombino R, Polesel J, Maione C, Scognamiglio P, Pisanti FA, Solmone M, Di Cicco P, Ippolito G, Franceschi S and Serraino D: Epidemiology of viral hepatitis infections in an area of southern Italy with high incidence rates of liver cancer. Eur J Cancer. 44:847–853. 2008. View Article : Google Scholar : PubMed/NCBI
2	El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
3	Castello G, Scala S, Palmieri G, Curley SA and Izzo F: HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin Immunol. 134:237–250. 2010. View Article : Google Scholar : PubMed/NCBI
4	Ueno Y, Sollano JD and Farrell GC: Prevention of hepatocellular carcinoma complicating chronic hepatitis C. J Gastroenterol Hepatol. 24:531–536. 2009. View Article : Google Scholar : PubMed/NCBI
5	Behne T and Copur MS: Biomarkers for hepatocellular carcinoma. Int J Hepatol. 2012:8590762012. View Article : Google Scholar : PubMed/NCBI
6	Forner A, Vilana R, Ayuso C, Bianchi L, Solé M, Ayuso JR, Boix L, Sala M, Varela M, Llovet JM, Brú C and Bruix J: Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology. 47:97–104. 2008. View Article : Google Scholar
7	Carmeliet P: Angiogenesis in health and disease. Nat Med. 9:653–660. 2003. View Article : Google Scholar : PubMed/NCBI
8	Semela D and Dufour JF: Angiogenesis and hepatocellular carcinoma. J Hepatol. 41:864–880. 2004. View Article : Google Scholar : PubMed/NCBI
9	Zhang JK, Pan PL, Wu YM, Xiao JJ and Peng JW: Expression of HER-2/neu oncogene in hepatocellular carcinoma and the clinical implications. Nan Fang Yi Ke Da Xue Xue Bao. 30:326–328. 2010.(In Chinese).
10	Li D, Chiu H, Gupta V and Chan DW: Validation of a multiplex immunoassay for serum angiogenic factors as biomarkers for aggressive prostate cancer. Clin Chim Acta. 413:1506–1511. 2012. View Article : Google Scholar : PubMed/NCBI
11	Capone F, Costantini S, Guerriero E, Calemma R, Napolitano M, Scala S, Izzo F and Castello G: Serum cytokine levels in patients with hepatocellular carcinoma. Eur Cytokine Netw. 21:99–104. 2010.PubMed/NCBI
12	Costantini S, Capone F, Guerriero E, Maio P, Colonna G and Castello G: Serum cytokine levels as putative prognostic markers in the progression of chronic HCV hepatitis leading to cirrhosis. Eur Cytokine Netw. 21:251–256. 2010.PubMed/NCBI
13	Costantini S, Capone F, Guerriero E, Marfella R, Sorice A, Maio P, Di Stasio M, Paolisso G, Castello G and Colonna G: Cytokinome profile of patients with type 2 diabetes and/or chronic hepatitis C infection. PLoS One. 7:e394862012. View Article : Google Scholar : PubMed/NCBI
14	Bacaksiz A, Sahin FI, Bilezikci B and Yilmaz Z: Determination of HER-2/Neu status in hepatocellular carcinoma cases. Genet Test. 12:211–214. 2008. View Article : Google Scholar : PubMed/NCBI
15	Rose-John S: Interleukin-6 biology is coordinated by membrane bound and soluble receptors. Acta Biochim Pol. 50:603–611. 2003.PubMed/NCBI
16	Rose-John S and Heinrich PC: Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J. 300:281–290. 1994.PubMed/NCBI
17	Montero-Julian FA: The soluble IL-6 receptors: serum levels and biological function. Cell Mol Biol. 47:583–597. 2001.PubMed/NCBI
18	Migita K, Abiru S, Maeda Y, Daikoku M, Ohata K, Nakamura M, Komori A, Yano K, Yatsuhashi H, Eguchi K and Ishibashi H: Serum levels of interleukin-6 and its soluble receptors in patients with hepatitis C virus infection. Hum Immunol. 67:27–32. 2006. View Article : Google Scholar : PubMed/NCBI
19	Maione D, Di Carlo E, Li W, Musiani P, Modesti A, Peters M, Rose-John S, Della Rocca C, Tripodi M, Lazzaro D, Taub R, Savino R and Ciliberto G: Coexpression of IL-6 and soluble IL-6R causes nodular regenerative hyperplasia and adenomas of the liver. EMBO J. 17:5588–5597. 1998. View Article : Google Scholar : PubMed/NCBI
20	Balci H, Akgun-Dar K, Gazioglu N, Kapucu A, Bolayirli M and Oz B: The relationship between prolactin (PRL), leptin, nitric oxide (NO), and cytokines in patients with hyperprolactinemia. Pituitary. 12:170–176. 2009. View Article : Google Scholar : PubMed/NCBI
21	Reeves HL and Friedman SL: Activation of hepatic stellate cells - a key issue in liver fibrosis. Front Biosci. 7:d808–d826. 2002. View Article : Google Scholar : PubMed/NCBI
22	Otte C, Otte JM, Strodthoff D, Bornstein SR, Fölsch UR, Mönig H and Kloehn S: Expression of leptin and leptin receptor during the development of liver fibrosis and cirrhosis. Exp Clin Endocrinol Diabetes. 112:10–17. 2004. View Article : Google Scholar : PubMed/NCBI
23	Katz SC, Pillarisetty VG, Bleier JI, Shah AB and DeMatteo RP: Liver sinusoidal endothelial cells are insufficient to activate T cells. J Immunol. 173:230–235. 2004. View Article : Google Scholar : PubMed/NCBI
24	Newman PJ and Newman DK: Signal transduction pathways mediated by PECAM-1. New roles for an old molecule in platelet and vascular biology. Arterioscler Thromb Vasc Biol. 23:953–964. 2003. View Article : Google Scholar : PubMed/NCBI
25	Kukla M, Zwirska-Korczala K, Gabriel A, Janczewska-Kazek E, Berdowska A, Wiczkowski A, Rybus-Kalinowska B, Kalinowski M, Ziolkowski A, Wozniak-Grygiel E, Waluga M and Nowak B: sPECAM-1 and sVCAM-1: role in pathogenesis and diagnosis of chronic hepatitis C and association with response to antiviral therapy. Therap Adv Gastroenterol. 2:79–90. 2009. View Article : Google Scholar : PubMed/NCBI
26	Kollerová J, Koller T and Payer J: Endocrine changes in liver disease. Vnitr Lek. 58:24–30. 2012.(In Slovak).
27	Simon-Holtorf J, Mönig H, Klomp HJ, Reinecke-Lüthge A, Fölsch UR and Kloehn S: Expression and distribution of prolactin receptor in normal, fibrotic, and cirrhotic human liver. Exp Clin Endocrinol Diabetes. 114:584–589. 2006. View Article : Google Scholar : PubMed/NCBI
28	Payer J, Koller T, Baqi L and Kollerova J: Prolactin levels in patients with cirrhosis increase with severity of liver disease. Endocrine Abstracts. 16:P4362008.
29	Gentile A, Trusolino L and Comoglio PM: The Met tyrosine kinase receptor in development and cancer. Cancer Metastasis Rev. 27:85–94. 2008. View Article : Google Scholar : PubMed/NCBI
30	Sahu A: Leptin signaling in the hypothalamus: emphasis on energy homeostasis and leptin resistance. Front Neuroendocrinol. 24:225–253. 2003. View Article : Google Scholar : PubMed/NCBI
31	Heinrich PC, Behrmann I, Haan S, Hermanns HM, Müller-Newen G and Schaper F: Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J. 15:1–20. 2003. View Article : Google Scholar : PubMed/NCBI
32	Pancholi S, Lykkesfeldt AE, Hilmi C, Banerjee S, Leary A, Drury S, Johnston S, Dowsett M and Martin L-A: ERBB2 influences the subcellular localization of the estrogen receptor in tamoxifen-resistant MCF-7 cells leading to the activation of AKT and RPS6KA2. Endocr Relat Cancer. 15:985–1002. 2008. View Article : Google Scholar : PubMed/NCBI
33	Naldini L, Vigna E, Narsimhan RP, Gaudino G, Zarnegar R, Michalopoulos GK and Comoglio PM: Hepatocyte growth factor (HGF) stimulates the tyrosine kinase activity of the receptor encoded by the proto-oncogene c-MET. Oncogene. 6:501–504. 1991.PubMed/NCBI